Nuwellis, Inc.

NasdaqCM NUWE

Nuwellis, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

Nuwellis, Inc. Interest Coverage Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Nuwellis, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -223.54, a 74.78% change year over year.
Nuwellis, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -886.32.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqCM: NUWE

Nuwellis, Inc.

CEO	Mr. Nestor Jaramillo Jr.
IPO Date	Feb. 16, 2012
Location	United States
Headquarters	12988 Valley View Road
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Key trends

Past 5 years